Kelun — Biotech to debut Phase 3 TroFuse — 005 sac — TMT endometrial cancer data at ESMO 2026 Presidential Symposium
Kelun-Biotech flagged multiple readouts for its TROP2 ADC sacituzumab tirumotecan at the ESMO 2026 congress in Madrid. Data will be presented in late October, with several studies slated for oral sessions. Key disclosures include late-stage lung cancer results, positioned to inform first-line treatment choices or post